-
January 25, 2023 05:25 PM IST YES Securities is bullish on Gland Pharma has recommended buy rating on the stock with a target price of Rs 1720 in its research report dated January 23, 2023.
-
January 24, 2023 10:08 PM IST Motilal Oswal is bullish on Gland Pharma recommended buy rating on the stock with a target price of Rs 1700 in its research report dated January 23, 2023.
- December 30, 2022 03:20 PM IST
Sharekhan recommended Hold rating on Gland Pharma with a target price of Rs 1689 in its research report dated December 29, 2022.
- December 01, 2022 12:23 PM IST
Sharekhan is bullish on Gland Pharma has recommended buy rating on the stock with a target price of Rs 2260 in its research report dated November 30, 2022.
- October 28, 2022 05:14 PM IST
Sharekhan is bullish on Gland Pharma has recommended buy rating on the stock with a target price of Rs 2260 in its research report dated October 27, 2022.
- July 21, 2022 09:28 PM IST
Sharekhan is bullish on Gland Pharma has recommended buy rating on the stock with a target price of Rs 3080 in its research report dated July 20, 2022.
- June 27, 2022 02:20 PM IST
Motilal Oswal is bullish on Gland Pharma has recommended buy rating on the stock with a target price of Rs 3700 in its research report dated June 25, 2022.
- May 21, 2022 08:30 PM IST
Sharekhan is bullish on Gland Pharma has recommended buy rating on the stock with a target price of Rs 3770 in its research report dated May 20, 2022.
- April 20, 2022 02:18 PM IST
Motilal Oswal is bullish on Gland Pharma recommended buy rating on the stock with a target price of Rs 4040 in its research report dated April 19, 2022.
- February 18, 2022 01:57 PM IST
We are entering increasing interest rate scenario. Liquidity is drying which simply means institutional fund flows would be much more selective and sensitive to quality aspect
- February 10, 2022 05:18 PM IST
Motilal Oswal is bullish on Gland Pharma has recommended buy rating on the stock with a target price of Rs 4240 in its research report dated January 22, 2022.
- December 01, 2021 03:44 PM IST
Emkay Global Financial is bullish on Gland Pharma has recommended buy rating on the stock with a target price of Rs 5000 in its research report dated November 29, 2021.
- November 30, 2021 04:31 PM IST
Sharekhan is bullish on Gland Pharma has recommended buy rating on the stock with a target price of Rs 4400 in its research report dated November 26, 2021.
- September 30, 2021 01:13 PM IST
Sharekhan is bullish on Gland Pharma has recommended buy rating on the stock with a target price of Rs 4400 in its research report dated September 29, 2021.
- July 22, 2021 05:00 PM IST
Sharekhan is bullish on Gland Pharma has recommended buy rating on the stock with a target price of Rs 4400 in its research report dated July 20, 2021.
- August 06, 2021 01:49 PM IST
Motilal Oswal is bullish on Gland Pharma recommended buy rating on the stock with a target price of Rs 4460 in its research report dated July 22, 2021.
- July 22, 2021 07:11 PM IST
While the US market is still expected to clock 18-20 per cent growth for Gland Pharma in FY22, the company’s foray into non-US markets would accelerate growth in the medium term
- July 06, 2021 10:41 AM IST
Sharekhan is bullish on Gland Pharma has recommended buy rating on the stock with a target price of Rs 4100 in its research report dated July 05, 2021.
- May 20, 2021 01:20 AM IST
Even after the contract with Sputnik V, it will have idle capacity available to pursue similar opportunities, including that of mRNA- platform-based ones.
- April 05, 2021 11:31 AM IST
Except phosgenation and fluorination, Suven Pharma is capable of handling every other chemistry. This adds to the scope for contract engagements in speciality chemicals and clinical development for pharma
- March 01, 2021 01:13 PM IST
Sharekhan is bullish on Gland Pharma has recommended buy rating on the stock with a target price of Rs 3040 in its research report dated February 26, 2021.
- February 19, 2021 10:46 AM IST
Valuation at a discount to peers, but significant scope for margin improvement
- February 12, 2021 11:06 AM IST
In the injectables space, Aurobindo Pharma remains constructive and targets to almost double from current annual sales base of $380 million to $650-700 million in three years backed by new plants in the US and Vizag
- January 25, 2021 09:35 AM IST
We believe dominance of profit/royalty-sharing aspect in the business model distinguishes Gland Pharma from other contract manufacturers
- November 09, 2020 12:54 PM IST
Gland Pharma's IPO provides an opportunity to take exposure to a steady earnings compounder with strong credentials
